Você procurou por: mucocutaneous (Inglês - Maltês)

severe mucocutaneous reactions
reazzjonijiet mukokutanji severi

mucocutaneous reactions, including stevens-johnson syndrome
reazzjonijiet mukokutanji, inkluż is-sindrome stevens-johnson

30 mucocutaneous, cmv viraemia/ syndrome and herpes simplex.
30 f' pazjenti fuq cellcept (2 g jew 3 g kuljum) flimkien ma 'immunosoppressanti oħra fi provi kliniċi kkontrollati f’ pazjenti bi trapjant tal- kliewi (tagħrif ta ’ 2 g), tal- qalb u tal- fwied li ġew osservati għal mill - inqas sena kienu candida mukokutanja, viremija/ sindromu b’ cmv u herpes simplex.

in patients experiencing a severe mucocutaneous reaction treatment must be discontinued.
f’pazjenti li jkun qed ikollhom reazzjoni mukokutanja severa, il-kura għandha titwaqqaf.

(< 200 cd4 lymphocytes/ mm3) and extensive mucocutaneous or visceral disease.
(< 200 cd4 limfoċiti/ mm3) u b' mard mukokutanju jew vixxerali estensiv.

severe mucocutaneous reactions (see also ‘special warnings and precautions for use’)
reazzjonijiet mukokutanji severi (ara wkoll ‘twissijiet speċjali u prekawzjonijiet għall-użu’)

patients experiencing a mucocutaneous reaction should not receive any further component of the zevalin regimen.
pazjenti li jkun qed ikollhom reazzjoni monokutanja m' għandhom jirċievu l- ebda komponent ieħor tal- kors ta ’ zevalin.

corneal ulcerations have been reported very rarely in patients receiving tarceva as a complication of mucocutaneous inflammation.
rrappurtati b’ mod rari ħafna bħala kumplikazzjoni ta ’ infjammazzjoni mukokutanja f’ pazjenti li qed jirċievu tarceva.

acute mucocutaneous toxicity has been reported in patients receiving hydroxycarbamide at doses several times above the therapeutic dose.
tossiċità mukokutanja akuta ġiet irrappurtata f’pazjenti li qed jingħataw hydroxycarbamide f’dożi ħafna drabi akbar mid-doża terapewtika.

early intervention has been shown to be efficacious in the treatment of mild to moderate joint, muscle and mucocutaneous bleeds.
Ġie muri li intervent bikri kien effikaċi fil-kura ta’ emorraġiji ħfief għal moderati tal-ġogi, tal-muskoli u mukokutanji.

across all clinical trials, mucocutaneous haemorrhage has been seen in up to 50% of avastin-treated patients.
tul il-provi kliniċi kollha, emorraġija mukokutanja dehret f’mhux aktar minn 50% tal-pazjenti kkurati b’avastin.

mucocutaneous reaction, including stevens johnson syndrome with fatal outcome, has been rarely reported in post-marketing experience.
soc meddra disturbi fil- ġilda u fit- tessuti ta ’ taħt il- ġilda rejazzjoni mukokutanja, inkluż is- sindromu ta ’ stevens- johnson b’ riżultat fatali, ġiet irrappurtata rarament f’ esperjenza ta ’ wara t- tqegħid fis- suq

clinical safety data suggest that the incidence of minor mucocutaneous haemorrhage (e.g. epistaxis) may be dose-dependent.
tagħrif dwar is-sigurtà klinika jissuġġerixxi li l-inċidenza ta’ emorraġija mukokutanja minuri (e.ż. epistassi) tista’ tkun dipendenti mid-doża.

it could not be determined whether these mucocutaneous adverse reactions were directly related to sprycel or to concomitant medicinal product. g gravitational oedema, localised oedema, oedema peripheral.
ma setax jiġi stabbilit jekk dawn ir-reazzjonijiet avversi mukokutanji kinux relatati direttament ma’ sprycel jew ma’ prodott mediċinali li ngħata fl-istess ħin. g edima gravitazzjonali, edima lokalizzata, edima periferali.

severe mucocutaneous reactions, including stevens-johnson syndrome with fatal outcome, have rarely been reported in association with the zevalin therapeutic regimen, which includes rituximab and radiolabelled zevalin.
rejazzjonijiet mukokutanji qawwija, inkluż is- sindromu ta ’ stevens- johnson b’ riżultat fatali, ġew irrappurtati rarament b’ assoċazzjoni ma ’ kors terapewtiku ta ’ zevalin, li jinkludu rituximab u zevalin radjutikkettjat.

owing to its primarily rxr-binding activity, bexarotene is less likely to cause mucocutaneous, nail, and hair toxicities; arthralgia; and myalgia; which are frequently reported with retinoic acid receptor (rar) -binding agents.
minħabba l-attività primarja tiegħu tat-twaħħil ma’ rxr, bexarotene hu inqas probabbli li jikkawża tossiċitajiet fil-ġilda u fil-membrani mukużi, fid-dwiefer u fix-xagħar; artralġja; u mijalġja; li huma b’mod frekwenti rrappurtati ma’ sustanzi li jeħlu tar-retinoic acid receptor (rar).